🇺🇸 FDA
Pipeline program

OD-07656, OD-07656, Entyvio 300 mg powder for concentrate for solution for infusion

OD-07656-201

Phase 2 small_molecule active

Quick answer

OD-07656, OD-07656, Entyvio 300 mg powder for concentrate for solution for infusion for Moderately to Severely Active Ulcerative Colitis is a Phase 2 program (small_molecule) at Odyssey Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Odyssey Therapeutics
Indication
Moderately to Severely Active Ulcerative Colitis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials